John V. Oyler
John V. Oyler | |
|---|---|
| Born | 1968 Pittsburgh, Pennsylvania, U.S. |
| Occupation | Business executive |
| Years active | 1990–present |
| Known for | Co-founder of BeiGene |
John V. Oyler (born 1968) is a prominent American business leader recognized for co-founding the biotechnology firm BeOne alongside biochemist Xiaodong Wang.
Early life and education
Raised in Pittsburgh, Pennsylvania, Oyler completed his undergraduate studies at the Massachusetts Institute of Technology, earning a degree in mechanical engineering in 1990.
Career
Oyler launched his professional journey as a consultant with McKinsey & Company, during which he frequently traveled to China. While working there, he pursued and obtained an MBA from Stanford University, subsequently continuing his tenure at McKinsey post-graduation.
In 1997, he joined the biotechnology organization Genta, specializing in oncology pharmaceuticals. There, Oyler spearheaded leadership restructuring efforts and successfully elevated the company’s market value from several million dollars to $1.7 billion.
In 1998, Oyler co-established Telephia, a telecommunications research enterprise, where he held the position of president until its acquisition by Nielsen Holdings in 2007. Between 2002 and 2004, he led Galenea, a company dedicated to developing treatments for psychiatric disorders.
Oyler returned to China in 2005 to co-found BioDuro, a contract research organization that was later acquired by PPD, Inc. in 2009.
BeiGene
In 2010, Oyler and Chinese biochemist Xiaodong Wang, whom he met during their time at BioDuro, co-founded BeiGene.
BeiGene has brought to market two significant cancer therapies: Tevimbra, a checkpoint inhibitor, and Brukinsa, an inhibitor targeting Bruton's tyrosine kinase. By 2023, the company had grown to employ approximately 10,000 individuals.
Personal life
Oyler is married and has one daughter.
